Ensysce Biosciences Announces Engagement of Alacrita Consulting
Engagement to aid expansion of the use of TAAP and MPAR® as well as the rapid development and commercialization of Ensysce's next generation opioids SAN DIEGO, CA / ACCESSWIRE / July 26, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced it has engaged Alacrita Consulting ("Alacrita"), a pharma and biotech consulting firm with extensive...
Read more









